NEF: A pleiotropic modulator of primate lentivirus infectivity and pathogenesis

Acta Microbiologica et Immunologica Hungarica

Volumn 53, Issue 1, 2006, Pages 51-75

  Balog, Katalin ^a   Minarovits, J ^a  

^a NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

Author keywords

AIDS therapy; Attenuated retrovirus; Defective HIV (dHIV); HIV; Long term non progressor; Master regulator; Nef; SIV; Viral interference

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; LENTIVIRUS; PRIMATES;

CD4 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; HLA ANTIGEN CLASS 1; NEF PROTEIN; VIRUS RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; BRAIN; DEFECTIVE VIRUS; GENETICS; HUMAN; IMMUNOLOGY; LENTIVIRINAE; MACROPHAGE; METABOLISM; MICROGLIA; MOUSE; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; RETROVIRUS INFECTION; REVIEW; T LYMPHOCYTE; VIROLOGY; VIRULENCE; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIGENS, CD4; BRAIN; CHEMOKINES; DEFECTIVE VIRUSES; GENE PRODUCTS, NEF; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LENTIVIRUS; LENTIVIRUS INFECTIONS; MACROPHAGES; MICE; MICROGLIA; RECEPTORS, CCR5; RECEPTORS, VIRUS; T-LYMPHOCYTES; VIRULENCE; VIRUS REPLICATION;

EID: 33744986058     PISSN: 12178950     EISSN: 15882640     Source Type: Journal    
DOI: 10.1556/AMicr.53.2006.1.4     Document Type: Article

References (117)

1. Harris, M.: From negative factor to a critical role in virus pathogenesis: the changing fortunes of Nef. J Gen Virol 77, 2379 (1996).
2. Miller, M. D., Warmerdam, M. T., Gaston, I., Greene, W. C., Feinberg, M. B.: The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 179, 101 (1994).
3. Brown, A., Moghaddam, S., Kawano, T., Cheng-Mayer, C.: Multiple human immunodeficiency virus type 1 Nef functions contribute to efficient replication in primary human macrophages. J Gen Virol 85, 1463 (2004).
4. Kestler III, H. W., Ringler, D. J., Mori, K., Panicali, D. L., Sehgal, P. K., Daniel, M. D., Desrosiers, R. C.: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651 (1991).
5. Kirchhoff, F., Greenough, T. C., Brettler, D. B., Sullivan, J. L., Desrosiers, R. C.: Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N Engl J Med 332, 228 (1995).
6. Deacon, N. J., Tsykin, A., Solomon, A., Smith, K., Ludford-Menting, M., Hooker, D. J., McPhee, D. A., Greenway, A. L., Ellett, A., Chatfield, C., Lawson, V. A., Crowe, S., Maerz, A., Sonza, S., Learmont, J., Sullivan, J. S., Cunningham, A., Dwyer, D., Dowton, D., Mills, J.: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 270, 988 (1995).
7. Salvi, R., Garbuglia, A. R., Di Caro, A., Pulciani, S., Montella, F., Benedetto, A.: Grossly defective nef gene sequences in a human immunodeficiency virus type 1 seropositive long-term nonprogressor. J Virol 72, 3646 (1998).
8. Learmont, J. C., Geczy, A. F., Mills, J., Ashton, L. J., Raynes-Greenow, C. H., Garsia, R. J., Dyer, W. B., McIntyre, L., Oelrichs, R. B., Rhodes, D. I., Deacon, N. J., Sullivan, J. S.: Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N Engl J Med 340, 1715 (1999).
9. Birch, M. R., Learmont J. C., Dyer, W. B., Deacon, N. J., Zaunders, J. J., Saksena, N., Cunningham, A. L., Mills, J., Sullivan, J. S.: An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). J Clin Virol 22, 263 (2001).
10. Casartelli, N., Di Matteo, G., Argentini, C., Cancrini, C., Bernardi, S., Castelli, G., Scarlatti, G., Plebani, A., Rossi, P., Doria, M.: Structural defects and variations in the HIV-1 nef gene from rapid, slow and non-progressor children. AIDS 17, 1291 (2003).
11. Hanna, Z., Kay, D. G., Cool, M., Jothy, S., Rebai, N., Jolicoeur, P.: Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol 72, 121 (1998a).
12. Hanna, Z., Kay, D. G., Rebai, N., Guimond, A., Jothy, S., Jolicoeur, P.: Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95, 163 (1998b).
13. Lindermann, D., Wilhelm, R., Renard, P., Althage, A., Zinkernagel, R., Mous, J.: Severe immunodeficiency associated with a human immunodeficiency virus 1 NEF/3'-long terminal repeat transgene. J Exp Med 179, 797 (1994).
14. Bour, S., Geleziunas, R., Wainberg, M. A.: The human immunodeficiency virus type 1 (HIV1) CD4 receptor and its central role in promotion of HIV-1 infection. Microbiological Reviews 59, 63 (1995).
15. Sawai, E. T., Cheng-Mayer, C., Luciw, P. A.: Nef and the Nef-associated kinase. Res Virol 148, 47 (1997).
16. Doms, R. W., Trono, D.: The plasma membrane as a combat zone in the HIV battlefield. Genes and Development 14, 2677 (2000).
17. Geyer, M., Fackler, O. T., Peterlin, B. M.: Structure-function relationships in HIV-1 Nef. EMBO Rep 2, 580 (2001).
18. Greenway, A. L., McPhee, D. A., Allen, K., Johnstone, R., Holloway, G., Mills, J., Azad, A., Sankovich, S., Lambert, P.: Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J Virol 76, 2692 (2002).
19. Pandori, M. W., Fitch, N. J., Craig, H. M., Richmann, D. D., Spina, C. A., Guatelli, J. C.: Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 70, 4283 (1996).
20. Welker, R., Kottler, H., Kalbitzer, H. R., Krausslich, H. G.: Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 219, 228 (1996).
21. Bukovsky, A. A., Dorfman, T., Weimann, A., Gottlinger, H. G.: Nef association with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J Virol 71, 1013 (1997).
22. Guatelli, J. C.: The positive influence of Nef on viral infectivity. Res Virol 148, 34 (1997).
23. Fackler, O. T., Kremmer, E., Mueller-Lantzsch, N.: Evidence for the association of Nef protein with HIV-2 virions. Virus Res 46, 105 (1996).
24. Piguet, V., Trono, D.: The Nef protein of primate lentiviruses. Rev Med Virol 9, 111 (1999).
25. Piguet, V., Schwartz, O., Le Gall, S., Trono, D.: The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 168, 51 (1999).
26. Ciuffi, A., Munoz, M., Bleiber, G., Favre, M., Stutz, F., Telenti, A., Meylan, P. R. A.: Interactions of processed Nef (58-206) with virion proteins of HIV type 1. AIDS Research and Human Retroviruses 20, 399 (2004).
27. Guy, B., Kieny, M. P., Riviere, Y., Le Peuch, C., Dott, K., Girard, M., Montagnier, L., Lecocq, J. P.: HIV F/3′ orf encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 330, 266 (1987).
28. Luo, T., Garcia, J. V.: Regulation of Nef function. Res Virol 148, 64 (1997).
29. Cullen, B. R.: HIV1 auxiliary proteins: Making connections in a dying cell. Cell 93, 685 (1998).
30. Little, S. J., Riggs, N. L., Chowers, M. Y., Fitch, N. J., Richman, D. D., Spina, C. A., Guatelli, J. C.: Cell surface CD4 downregulation and resistance to superinfection induced by a defective provirus of HIV-1. Virology 205, 578 (1994).
31. Federico, M., Nappi, F., Ferrari, G., Chelucci, C., Mavilio, F., Verani, P.: A nonproducer, interfering human immunodeficiency virus (HIV) type 1 provirus can be transduced through a murine leukemia virus-based retroviral vector: recovery of an anti-HIV mouse/human pseudotype retrovirus. J Virol 69, 6618 (1995).
32. Federico, M., Bona, R., D'Aloja, P., Baiocchi, M., Pugliese, K., Nappi, F., Chelucci, C., Mavilio, F., Verani, P.: Anti-HIV viral interference induced by retroviral vectors expressing a nonproducer HIV-1 variant. Acta Haematol 95, 199 (1996).
33. Benson, R. E., Sanfridson, A., Ottinger, J. S., Doyle, C., Cullen, B. R.: Downregulation of surface CD4 expression by simian immunodeficiency virus Nef prevents viral superinfection. J Exp Med 177, 1561 (1993).
34. Michel, N., Allespach, I., Venzke, S., Fackler, O. T., Keppler, O. T.: The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell-surface CCR5 and CD4. Curr Biol 15, 714 (2005).
35. Mangasarian, A., Trono, D.: The multifaceted role of HIV Nef. Res Virol 148, 30 (1997).
36. Benichou, S., Liu, L. X., Erdtmann, L., Selig, L., Benarous, R.: Use of the two-hybrid system to identify cellular partners of the HIV1 Nef protein. Res Virol 148, 71 (1997).
37. Greenway, A., McPhee, D.: HIV1 Nef: the Machiavelli of cellular activation. Res Virol 148, 58 (1997).
38. Le Gall, S., Heard, J. M., Schwartz, O.: Analysis of Nef-induced MHC-I endocytosis. Res Virol 148, 43 (1997).
39. Derrien, M., Pizzato, N., Dolcini, G., Menu, E., Chaouat, G., Lenfant, F., Barre-Sinoussi, F., Bouteiller, P. L.: Human immunodeficiency virus 1 downregulates cell surface expression of the non-classical major histocompatibility class I molecule HLA-G1. J Gen Virol 85, 1945 (2004).
40. Williams, M., Roeth, J. F., Kasper, M. R., Fleis, R. I., Przybycin, C. G., Collins, K. L.: Direct binding of HIV1 Nef to the Major Histocompatibility Complex ClassI (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol 76, 12173 (2002).
41. Keir, M. E., Stoddart, C. A., Linquist-Stepps, V., Moreno, M. E., McCune, J. M.: IFN-α secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J Immunol 168, 325 (2002).
42. Béládi, I.: Avian and human interferon studies initiated by György Ivánovics. In: 13th International Congress of the Hungarian Society for Microbiology. Book of Abstracts, 1999, p. 7.
43. Woelk, C. H., Ottones, F., Plotkin, C. R., Du, P., Royer, C. D., Rought, S. E., Lozach, J., Sasik, R., Kornbluth, R. S., Richman, D. D., Corbeil, J.: Interferon gene expression following HIV type 1 infection of monocyte-derived macrophages. AIDS Res. Human Retroviruses 20, 1210 (2004).
44. Wiskerchen, M., Cheng-Mayer, C.: HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis. Virology 224, 292 (1996).
45. Adachi, A., Oshima, Y.: Cell-dependent functional roles of HIV-1 Nef for virus replication (review). Int J Mol Med 3, 427 (1999).
46. Kotov, A., Zhou, J., Flicker, P., Aiken, C.: Association of Nef with the Human Immunodeficiency Virus Type 1 Core. J Virol 73, 8824 (1999).
47. Stoddart, C. A., Geleziunas, R., Ferrell, S., Linquist-Stepps, V., Moreno, M. E., Bare, C., Xu, W., Yonemoto, W., Bresnahan, P. A., McCune, J. M., Greene, W. C.: Human Immunodeficiency Virus Type 1 Nef-Mediated Downregulation of CD4 Correlates with Nef Enhancement of Viral Pathogenesis. J Virol 77, 2124 (2003).
48. Zheng, Y. H., Plemenitas, A., Fielding, C. J., Peterlin, B. M.: Nef increases the synthesis of and transports cholesterol to lipid rafts and HIV-1 progeny virions. Proc Natl Acad Sci USA 100, 8460 (2003).
49. Costa, L. J., Zheng, Y. H., Sabotic, J., Mak, J., Fackler, O. T., Peterlin, B. M.: Nef binds p6* in GagPol during Replication of Human Immunodeficiency Virus Type 1. J Virol 78, 5311 (2004).
50. Bell, I., Ashman, C., Maughan, J., Hooker, E., Cook, F., Reinhart, T. A.: Association of simian immunodeficiency virus Nef with the T-cell receptor (TCR) ζ chain leads to TCR down-modulation. J Gen Virol 79, 2717 (1998).
51. Baur, A. S., Sass, G., Laffert, B., Willbold, D., Cheng-Mayer, C., Peterlin, B. M.: The N-terminus of Nef from HIV-1/SIV associates with a protein complex containing Lck and a serine kinase. Immunity 6, 283 (1997).
52. Krautkrämer, E., Giese, S. I., Gasteier, J. E., Muranyi, W., Fackler, O. T.: Human immunodeficiency virus Type 1 Nef activates p21-activated kinase via recruitment into lipid rafts. J Virol 78, 4085 (2004).
53. Swingler, S., Mann, A., Jacqué, J. M., Brichacek, B., Sasseville, V. G., Williams, K., Lackner, A. A., Janoff, E. N., Wang, R., Fisher, D., Stevenson, M.: HIV-1 Nef mediates lymphocyte chemotaxis and activation by infected macrophages. Nature Medicine 5, 997 (1999).
54. Brown, A., Wang, X., Sawai, E., Cheng-Mayer, C.: Activation of the PAK-related kinase by human immunodeficiency virus type 1 Nef in primary human peripheral blood lymphocytes and macrophages leads to phosphorylation of a PIX-p95 complex. J Virol 73, 9899 (1999).
55. Federico, M., Percario, Z., Olivetta, E., Fiorucci, G., Muratori, C., Micheli, A., Romeo, G., Affabris, E.: HIV-1 Nef activates STAT1 in human monocytes/macrophages through the release of soluble factors. Blood 98, 2752 (2001).
56. Aquaro, S., Calio, R., Balzarini, J., Bellocchi, M. C., Garaci, E., Perno, C. F.: Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Research 55, 209 (2002).
57. Smith, D. G., Guillemin, G. J., Pemberton, L., Kerr, S., Nath, A., Smythe, G. A., Brew, B. J.: Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat. J Neurovirol 7, 56 (2001).
58. Speth, C., Schabetsberger, T., Mohsenipour, I., Stockl, G., Wurzner, R., Stoiber, H., Lass-Florl, C., Dierich, M. P.: Mechanism of human immunodeficiency virus-induced complement expression in astrocytes and neurons. J Virol 76, 3179 (2002).
59. Toggas, S. M., Masliah, E., Rockenstein, E. M., Rall, G. F., Abraham, C. R., Mucke, L.: Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367, 188 (1994).
60. van de Bovenkamp, M., Nottet, H. S., Pereira, C. F.: Interactions of human immunodeficiency virus-1 proteins with neurons: possible role in the development of human immunodeficiency virus-1-associated dementia. Eur J Clin Invest 32, 619 (2002).
61. Overholser, E. D., Coleman, G. D., Bennett, J. L., Casaday, R. J., Zink, M. C., Barber, S. A., Clements, J. E.: Expression of simian immunodeficiency virus (SIV) Nef in astrocytes during acute and terminal infection and requirement of Nef for optimal replication of neurovirulent SIV in vitro. J Virol 77, 6855 (2003).
62. Si, Q., Kim, M. O., Zhao, M. L., Landau, N. R., Goldstein, H., Lee, S.: Vpr- and NEF-dependent induction of Rantes/CCL5 in microglial cells. Virology 301, 342 (2002).
63. Koedel, U., Kohleisen, B., Sporer, B., Lahrtz, F., Ovod, V., Fontana, A., Erfle, V., Pfister, H. W.: HIV type 1 Nef protein is a viral factor for leukocyte recruitment into the central nervous system. J Immunol 163, 1237 (1999).
64. Simmons, A., Aluvihare, V., McMichael, A.: Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14, 763 (2001).
65. Steffens, C. M., Hope T. J.: Recent advances in the understanding of HIV accessory protein function. AIDS 15 (suppl. 5), S21 (2001).
66. Arendt, C. W., Littman, D. R.: HIV: master of the host cell. Genome Biology 2 (11), Reviews 1030.1 (2001).
67. Fujinaga, K., Zhong, Q., Nakaya, T., Kameoka, M., Meguro, T., Yamada, K., Ikuta, K.: Extracellular Nef protein regulates productive HIV-1 infection from latency. J Immunol 155, 5289 (1995).
68. Tobiume, M., Fujinaga, K., Suzuki, S., Komoto, S., Mukai, T., Ikuta, K.: Extracellular Nef protein activates signal transduction pathway from Ras to mitogen-activated protein-kinase cascades that leads to activation of human immunodeficiency virus from latency. AIDS Res Hum Retroviruses 18, 461 (2002).
69. Torres, B. A., Tanabe, T., Johnson, H. M.: Characterization of Nef-induced T cell proliferation. Biochem Biophys Res Commun 225, 54 (1996).
70. Azad, A. A.: Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells? Biochem Biophys Res Commun 267, 677 (2000).
71. Finkel, T. H., Tudor-Williams, G., Banda, N. K., Cotton, M. F., Curiel, T., Monks, C., Baba, T. W., Ruprecht, R. M., Kupfer, A.: Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV-infected lymph nodes. Nat Med 1, 129 (1995).
72. Alimonti, J. B., Ball, T. B., Fowke, K. R.: Mechanisms of CD4+ T lymphocyte cell death in human immunodeficiency virus infection and AIDS. J Gen Virol 84, 1649 (2003).
73. Brigino, E., Haraguchi, S., Koutsonikolis, A., Cianciolo, G. J., Owens, U., Good, R. A., Day, N. K.: Interleukin 10 is induced by recombinant HIV-1 Nef protein involving the calcium/calmodulin-dependent phosphodiesterase signal transduction pathway. Proc Natl Acad Sci USA 94, 3178 (1997).
74. Collette, Y., Chang, H. L., Cerdan, C., Chambost, H., Algarte, M., Mawas, C., Imbert, J., Burny, A., Olive, D.: Specific Th1 cytokine down-regulation associated with primary clinically derived human immunodeficiency virus type 1 Nef gene-induced expression. J Immunol 156, 360 (1996).
75. Corbeil, J., Sheeter, D., Genini, D., Rought, S., Leoni, L., Du, P., Ferguson, M., Masys, D. R., Welsh, J. B., Fink, J. L., Sasik, R., Huang, D., Drenkow, J., Richman, D. D., Gingeras T.: Temporal gene regulation during HIV-1 infection of human CD4+ T cells. Genome Res 11, 1198 (2001).
76. Curtain, C. C., Separovic, F., Rivett, D., Kirkpatrick, A., Waring, A. J., Gordon, L. M., Azad, A. A.: Fusogenic activity of amino-terminal region of HIV type 1 Nef protein. AIDS Res Hum Retroviruses 10, 1231 (1994).
77. + T cells for apoptosis by interacting with CXCR4 surface receptors. J Virol 78, 3099 (2004).
78. Pugliese, A., Cantamessa, C., Saini, A., Piragino, A., Gennero, L., Martini, C., Torre, D.: Effects of the exogenous Nef protein on HTV-1 target cells. Cell Biochem Fund 17, 183 (1999).
79. Alessandrini, L., Santarcangelo, A. C., Olivetta, E., Ferrantelli, F., d'Aloja, P., Pugliese, K., Pelosi, E., Chelucci, C., Mattia, G., Peschle, C., Verani, P., Federico, M.: T-tropic human immunodeficiency virus (HIV) type 1 Nef protein enters human monocyte-macrophages and induces resistance to HIV replication: a possible mechanism of HIV T-tropic emergence in AIDS. J Gen Virol 81, 2905 (2000).
80. Fujii, Y., Otake, K., Tashiro, M., Adachi, A.: Soluble Nef antigen of HIV-1 is cytotoxic for human CD4+ T cells. FEBS Lett 393, 93 (1996).
81. Fenyo, E. M.: Biological phenotype and coreceptor usage of human immunodeficiency virus (a short review). Acta Microbiol Immunol Hung 47, 131 (2000).
82. Connor, R. I., Montefiori, D. C., Binley, J. M., Moore, J. P., Bonhoeffer, S., Gettie, A., Fenamore, E. A., Sheridan, K. E., Ho, D. D., Dailey, P. J., Marx, P. A.: Temporal analyses of virus replication, immune responses, and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 72, 7501 (1998).
83. Chakrabarti, L. A., Metzner, K. J., Ivanovic, T., Cheng, H., Louis-Virelizier, J., Connor, R. I., Cheng-Mayer, C.: A truncated form of Nef selected during pathogenic reversion of simian immunodeficiency virus SIVmac239Δnef increases viral replication. J Virol 77, 1245 (2003).
84. Stove, V., Naessens, E., Stove, C., Swigut, T., Plum, J., Verhasselt, B.: Signaling but not trafficking function of HIV-1 protein Nef is essential for Nef-induced defects in human intrathymic T-cell development. Blood 102, 2925 (2003).
85. Federico, M.: Targeting the Nef induced increase of HIV infectivity. Curr Drug Targets Immune Endocr Metab Disord 4, 321 (2004).
86. Choi, H. J., Smithgall, T. E.: Conserved residues in the HIV-1 Nef hydrophobic pocket are essential for recruitment and activation of the Hck tyrosine kinase. J Mol Biol 343, 1255 (2004).
87. Moarefi, I., LaFevre-Bernt, M., Sicheri, F., Huse, M., Lee, C. H., Kuriyan, J., Miller, W. T.: Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385, 650 (1997).
88. Lee, C. H., Saksela, K., Mirza, U. A., Chait, B. T., Kuriyan, J.: Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 85, 931 (1996).
89. Arold, S., Franken, P., Strub, M. P., Hoh, F., Benichou, S., Benarous, R., Dumas, C.: The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling. Structure 5, 1361 (1997).
90. Carl, S., Iafrate, A. J., Lang, S. M., Stolte, N., Stahl-Hennig, C., Matz-Rensing, K., Fuchs, D., Skowronski, J., Kirchhoff, F.: Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques. J Virol 74, 4155 (2000).
91. Grzesiek, S., Bax, A., Hu, J. S., Kaufman, J., Palmer, I., Stahl, S. J., Tjandra, N., Wingfield, P. T.: Refined solution structure and backbone dynamics of HIV-1 Nef. Protein Sci 6, 1248 (1997).
92. Olszewski, A., Sato, K., Aron, Z. D., Cohen, F., Harris, A., McDougall, B. R., Robinson, W. E., Overman, L. E., Weiss, G. A.: Guanidine alkaloid analogs as inhibitors of HIV-1 Nef interactions with p53, actin, and p561ck. Proc Natl Acad Sci USA 101, 14079 (2004).
93. Schiavoni, I., Muratori, C., Piacentini, V., Giammarioli, A. M., Federico, M.: The HIV-1 Nef protein: how an AIDS pathogenetic factor turns to a tool for combating AIDS. Curr Drug Targets Immune Endocr Metabol Disord 4, 19 (2004).
94. Lichterfeld, M., Yu, X. G., Cohen, D., Addo, M. M., Malenfant, J., Perkins, B., Pae, E., Johnston, M. N., Strick, D., Allen, T. M., Rosenberg, E. S., Korber, B., Walker, B. D., Altfeld, M.: HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-I infection despite a relatively high degree of genetic diversity. AIDS 18, 1383 (2004).
95. Kaufmann, D. E., Bailey, P. M., Sidney, J., Wagner, B., Norris, P. J., Johnston, M. N., Cosimi, L. A., Addo, M. M., Lichterfeld, M., Altfeld, M., Frahm, N., Brander, C., Sette, A., Walker, B. D., Rosenberg, E. S.: Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 78, 4463 (2004).
96. Ruprecht, R. M.: Live attenuated AIDS viruses as vaccines: promise or peril? Immunol Rev 170, 135 (1999).
97. Jekle, A., Schramm, B., Jayakumar, P., Trautner, V., Schols, D., DeClercq, E., Mills, J., Crowe, S. M., Goldsmith, M. A.: Coreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence. J Virol 76, 6966 (2002).
98. Enose, Y., Kita, M., Yamamoto, T., Suzuki, H., Miyake, A., Horiuchi, R., Ibuki, K., Kaneyasu, K., Kuwata, T., Takahashi, E., Sakai, K., Shinohara, K., Miura, T., Hayami, M.: Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination. Arch Virol 149, 1705 (2004).
99. Stahl-Hennig, C., Gundlach, B. R., Dittmer, U., ten Haaft, P., Heeney, J., Zou, W., Emilie, D., Sopper, S., Uberla, K.: Replication, immunogenicity, and protective properties of live-attenuated simian immunodeficiency viruses expressing interleukin-4 or interferon-gamma. Virology 305, 473 (2003).
100. Daniel, M. D., Kirchhoff, F., Czajak, S. C., Sehgal, P. K., Desrosiers, R. C.: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938 (1992).
101. Clements, J. E., Montelaro, R. C., Zink, M. C., Amedee, A. M., Miller, S., Trichel, A. M., Jagerski, B., Hauer, D., Martin, L. N., Bohm, R. P., Murphey-Corb, M.: Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J Virol 69, 2737 (1995).
102. Wyand, M. S., Manson, K. H., Garcia-Moll, M., Montefiori, D., Desrosiers, R. C.: Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol 70, 3724 (1996).
103. Van Rompay, K. K. A., Otsyula, M. G., Tarara, R. P., Canfield, D. R., Berardi, C. J., McChesney, M. B., Marthus, M. L.: Vaccination of pregnant macaques protects newborns against mucosal simian immunodeficiency virus infection. J Infect Dis 173, 1327 (1996).
104. Dittmer, U., Nisslein, T., Bodemer, W., Petry, H., Sauermann, U., Stahl-Hennig, C., Hunsmann, G.: Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology 212, 392 (1995).
105. Cranage, M. P., Whatmore, A. M., Sharpe, S. A., Cook, N., Polyanskaya, N., Leech, S., Smith, J. D., Rud, E. W., Dennis, M. J., Hall, G. A.: Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 228, 143 (1997).
106. Norley, S., Beer, B., Binninger-Schninzel, D., Cosma, C., Kurth, R.: Protection from pathogenic SIVmac challange following short-term infection with a nef-deficient attenuated virus. Virology 219, 195 (1996).
107. Sharpe, S. A., Whatmore, A. M., Hall, G. A., Cranage, M. P.: Macaques infected with attenuated simian immunodeficiency virus resist superinfection with virulence-revertant virus. J Gen Virol 78, 1923 (1997).
108. Sharpe, S. A., Cope, A., Dowall, S., Berry, N., Ham, C., Heeney, J., Hopkins, D., Easterbrook, L., Dennis, M., Almond, N., Cranage, M.: Macaques infected long-term with attenuated simian immunodeficiency virus (SIVmac) remain resistant to wild-type challenge, despite declining cytotoxic T lymphocyte responses to an immunodominant epitope. J Gen Virol 85, 2591 (2004).
109. Langlois, A. J., Desrosiers, R. C., Lewis, M. G., KewalRamani, V. N., Littman, D. R., Zhou, J. Y., Manson, K., Wyand, M. S., Bolognesi, D. P., Montefiori, D. C.: Neutralizing antibodies in sera from macaques immunized with attenuated simian immunodeficiency virus. J Virol 72, 9650 (1998).
110. Gundlach, B. R., Reiprich, S., Sopper, S., Means, R. E., Dittmer, U., Mätz-Rensing, K., Stahl-Hennig, C., Überla, K.: Env-independent protection induced by live, attenuated simian immunodeficiency virus vaccines. J Virol 72, 7846 (1998).
111. Khatissian, E., Monceaux, V., Cumont, M. C., Kieny, M. P., Aubertin, A. M., Hurtrel, B.: Persistence of pathogenic challenge virus in macaques protected by simian immunodeficiency virus SIVmacDeltanef. J Virol 75, 1507 (2001).
112. Nilsson, C., Makitalo, B., Thorstensson, R., Norley, S., Binninger-Schinzel, D., Cranage, M., Rud, E., Biberfeld, G., Putkonen, P.: Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS 12, 2261 (1998).
113. Wei, M., Xing, H., Hong, K., Huang, H., Tang, H., Qin, G., Shao, Y.: Biased G-to-A hypermutation in HIV-1 proviral DNA from a long term non-progressor. AIDS 18, 1863 (2004).
114. Volsky, D. J., Simm, M., Shahabuddin, M., Li, G., Chao, W., Potash, M. J.: Interference to human immunodeficiency virus type 1 infection in the absence of the downmodulation of the principal virus receptor, CD4. J Virol 70, 3823 (1996).
115. Berencsi, G., Minarovits, J., Nasz, I., Földes, I.: Prospects for the control of AIDS patients by introducing defective-HIV harbouring leukocytes. Med Hypotheses 30, 223 (1989).
116. Minarovits, J., Berencsi, G., Nasz, I., Földes, I.: Therapy of AIDS patients - classical strategies and proposals for novel therapeutic approaches (a short review). Acta Microbiol Hung 35, 361 (1988).
117. Czub, M., McAtee, F. J., Czub, S., Lynch, W. P., Portis, J. L.: Prevention of retrovirus-induced neurological disease by infection with a nonneuropathogenic retrovirus. Virology 206, 372 (1995).